Semaglutide cut 6-month MACE by 50% in non-diabetic obese ACS patients post-PCI
Background
Patients experiencing an acute coronary syndrome (ACS), especially those who are obese and non-diabetic, face a high risk of recurrent cardiovascular events even after successful percutaneous coronary intervention (PCI). Traditional management often focuses on lipid and blood pressure control, but the underlying metabolic dysfunction in obesity contributes significantly to this residual risk. Glucagon-like peptide-1 receptor (GLP-1R) agonists like semaglutide have demonstrated cardiovascular benefits in diabetic populations, but their role in non-diabetic obese individuals post-ACS, particularly in East Asian cohorts, remains an area of active investigation.
Study Design
This multicenter retrospective cohort study enrolled a total of 344 non-diabetic obese patients with ACS who underwent PCI between May 2020 and December 2024. Patients were divided into a semaglutide group (112 patients) and a control group (232 patients). Propensity score matching (PSM) was applied to balance baseline characteristics. The primary endpoint was the incidence of 6-month major adverse cardiovascular events (MACE), while secondary endpoints included changes in cardiac troponin I (cTnI) levels, metabolic parameters (fasting blood glucose, HbA1c, lipids), and left ventricular ejection fraction (LVEF) at 6-month follow-up.
Results
After propensity score matching, the semaglutide group demonstrated significantly lower rates of 6-month MACE compared to the control group (11.6% vs. 23.2%, p=0.034), representing a 50% relative risk reduction. Unplanned revascularization was also substantially lower in the semaglutide arm (4.7% vs. 13.4%, p=0.033), a 65% reduction. Patients receiving semaglutide showed faster improvement in cTnI levels. Both groups improved blood lipid profiles and LVEF post-PCI, but the semaglutide group achieved superior outcomes across several key metrics:
The magnitude of improvement in
BMIwas 2.49 ± 3.27 kg/m² in the semaglutide group versus 0.78 ± 2.76 kg/m² in controls (p=0.002), andLVEFimproved by 5.73 ± 8.07% vs. 2.66 ± 8.09% (p=0.005). Further significant reductions were observed in fasting blood glucose (0.49 ± 0.75mmol/L vs. 0.03 ± 0.83mmol/L, p<0.0001),LDL-C(1.78 ± 1.22mmol/L vs. 0.83 ± 0.94mmol/L, p<0.0001), andTG(0.98 ± 1.02mmol/L vs. 0.63 ± 0.70mmol/L, p=0.003).
Key Findings
- Semaglutide reduced 6-month
MACEby 50% (11.6% vs. 23.2%, p=0.034) in non-diabetic obese ACS patients. - Unplanned revascularization was 65% lower in the semaglutide group (4.7% vs. 13.4%, p=0.033).
- Semaglutide led to significantly greater
BMIreduction (2.49 kg/m² vs. 0.78 kg/m², p=0.002). - Improved
LVEFby 5.73% vs. 2.66% in the control group (p=0.005). - Greater reductions in
FBG,LDL-C, andTGwere observed with semaglutide (all p<0.0001 or p=0.003).
Why It Matters
This study provides compelling evidence that semaglutide offers significant cardiovascular protection and metabolic benefits for non-diabetic obese patients following an ACS event and PCI. The observed 50% reduction in MACE and 65% reduction in unplanned revascularization within 6 months suggests a crucial role for GLP-1R agonists beyond diabetes management. For clinicians, this implies that semaglutide could be a valuable adjunctive therapy in this high-risk population, potentially altering the trajectory of secondary prevention. While the specific dosing regimen is not detailed, the findings support considering GLP-1R agonists for their pleiotropic effects on cardiac function, inflammation, and metabolic health, even in the absence of diabetes. This expands the potential clinical utility of semaglutide and warrants further prospective investigation to establish optimal protocols.
semaglutide
acute-coronary-syndrome
obesity
cardiovascular
glp-1-agonist
retrospective-cohort